37 completed. 37 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 37 |
| Phase 2 | 6 | Completed 6 |
Follow Dry Eye: new trials by email Literature Review of Dry Eye trials Research Report on Dry Eye
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease SJP-0132, Placebo - Dry Eye | Phase 3 | Completed | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. | 427 | 2024-12-30 | 2025-11-26 |
| Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye. recombinant human insulin, Autologous serum - Dry Eye, Sjogren Syndrome | Phase 3 | Completed | Instituto de Oftalmología Fundación Conde de Valenciana | 25 | 2024-02-01 | 2026-08-27 |
| Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye Icross tear substitute, Hyabak tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 30 | 2023-11-01 | 2024-07-26 |
| Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients TJO-083, Diquafosol ophthalmic sodium solution 3% - Dry Eye, Dry Eye Syndromes | Phase 3 | Completed | Taejoon Pharmaceutical Co., Ltd. | 271 | 2023-07-14 | 2025-04-22 |
| Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease Trimix tear substitutes, Hyaluronic acid tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 124 | 2023-07-01 | 2024-06-27 |
| Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free - Dry Eye | Phase 3 | Completed | Research Insight LLC | 59 | 2022-06-03 | 2023-01-04 |
| Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) Oxervate, Vehicle - Dry Eye | Phase 3 | Completed | Dompé Farmaceutici S.p.A | 104 | 2022-01-19 | 2024-06-07 |
| A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution - Dry Eye, Dry Eye Syndromes | Phase 3 | Completed | Palatin Technologies, Inc | 575 | 2021-12-30 | 2024-10-17 |
| A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye 0.25% Tanfanercept Ophthalmic Solution, Placebo - Dry Eye | Phase 3 | Completed | HanAll BioPharma Co., Ltd. | 260 | 2021-11-18 | 2023-10-23 |
| The Effect of a Novel Blueberry Supplement on Dry Eye Disease Blueberry gummy, Placebo gummy - Dry Eye | Phase 3 | Completed | SightSage Foods and Nutrition Inc. | 68 | 2021-09-09 | 2023-01-20 |
| The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 361 | 2021-08-28 | 2025-03-18 |
| ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease ALY688 Ophthalmic Solution - Dry Eye | Phase 2 / Phase 3 | Completed | Allysta Pharmaceutical | 922 | 2021-05-19 | 2023-03-16 |
| A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye HBM9036 0.25% Ophthalmic Solution, Placebo - Dry Eye | Phase 3 | Completed | Harbour BioMed (Guangzhou) Co. Ltd. | 577 | 2021-02-25 | 2026-04-28 |
| The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution - Dry Eye, Dry Eye Syndromes | Phase 2 / Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 329 | 2020-11-21 | 2025-03-19 |
| Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease CsA Ophthalmic Gel, Placebo, Hypromellose Eye Drop - Dry Eye | Phase 3 | Completed | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 644 | 2020-11-05 | 2022-04-29 |
| Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease Omega 3 fatty acid, Placebos - Dry Eye | Phase 3 | Completed | OmegaD LLC | 322 | 2019-11-18 | 2024-07-29 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 RGN-259, Placebo - Dry Eye Syndromes, Dry Eye | Phase 3 | Completed | ReGenTree, LLC | 700 | 2019-05-24 | 2026-08-28 |
| The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID - Dry Eye | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 422 | 2019-04-16 | 2025-01-23 |
| Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Tavilermide ophthalmic solution, Placebo - Keratoconjunctivitis Sicca, Dry Eye | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 623 | 2019-03-28 | 2023-04-05 |
| A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes HL036 Ophthalmic Solution, Placebo - Dry Eye | Phase 3 | Completed | HanAll BioPharma Co., Ltd. | 637 | 2019-03-10 | 2022-04-14 |
Showing 20 of 37. Sign in to see all of them.
Dry Eye Syndromes (37) · Sjogren's Syndrome (4) · Keratoconjunctivitis Sicca (3) · Autoimmune Diseases (1) · Conjunctival Diseases (1) · Corneal Diseases (1) · Eye Diseases (1) · Insulin Resistance (1)
Lacrimal Apparatus Diseases (37) · Eye Diseases (36) · Arthritis (4) · Arthritis, Rheumatoid (4) · Connective Tissue Diseases (4) · Immune System Diseases (4) · Joint Diseases (4) · Mouth Diseases (4) · Musculoskeletal Diseases (4) · Rheumatic Diseases (4) · Salivary Gland Diseases (4) · Skin and Connective Tissue Diseases (4) · Stomatognathic Diseases (4) · Xerostomia (4) · Autoimmune Diseases (3)
Ophthalmic Solutions (2) · Acupuncture Therapy (1) · Brimonidine Tartrate (1) · Carboxymethylcellulose Sodium (1) · Chondroitin (1) · Cyclosporine (1) · Cyclosporins (1) · Fatty Acids, Omega-3 (1) · Fluorometholone (1) · Glycerol (1) · Hydroxychloroquine (1) · Loteprednol Etabonate (1) · Lubricant Eye Drops (1) · Pilocarpine (1) · Pregabalin (1)
Aldeyra Therapeutics, Inc. (3) · HanAll BioPharma Co., Ltd. (2) · OmegaD LLC (2) · University of Seville (2) · Alcon Research (1) · Alexandria University (1) · Allergan (1) · Allysta Pharmaceutical (1) · Dompé Farmaceutici S.p.A (1) · Eyegate Pharmaceuticals, Inc. (1) · Federal University of São Paulo (1) · Harbour BioMed (Guangzhou) Co. Ltd. (1) · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (1) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Korea Institute of Oriental Medicine (1)
United States (19) · China (3) · South Korea (3) · Spain (3) · Japan (2) · Mexico (2) · Brazil (1) · Canada (1) · Egypt (1) · Italy (1)
Anat Galor, MD, MSPH (1) · Brian Dodge (1) · Ehab Mossallam, PhD (1) · Eiji Murakami (1) · Flavio Mantelli, MD (1) · Gaafar Ragab (1) · Gail L Torkildsen, MD (1) · John Hovanesian, MD (1) · Karen Meerovitch, PhD (1) · Kazunori Omatsu (1) · Margarita Calonge-Cano, MD, PhD (1) · Mark Curtis, O.D. (1) · Maureen G Maguire, PhD (1)
PMID 11879137, PMID 14508260, PMID 15604871, PMID 16371776, PMID 17043506, PMID 18848318, PMID 20735287, PMID 21078194, PMID 22615787, PMID 22914501, PMID 26065354, PMID 26365210, PMID 27366013, PMID 27645318, PMID 28079022, PMID 28777385, PMID 29432648, PMID 29545413, PMID 29652551, PMID 29883769, PMID 29970389, PMID 30161055, PMID 31022469, PMID 31116166, PMID 31373862, PMID 31425752, PMID 31445751, PMID 31489258, PMID 32097181, PMID 32821497, PMID 33096271, PMID 33290317, PMID 33530719, PMID 33561944, PMID 34294637, PMID 36575626, PMID 36729473, PMID 37209594, PMID 38345056, PMID 38391283, PMID 39079754, PMID 42803882
U10EY022879 (1), U10EY022881 (1)